Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK6 | P43250 | 10/20 | 0.39 |
| ▸ | AURKA | O14965 | 3/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.33 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312137 | 0.90 | GRK6 (0.36) | GRK6AURKANTRK1 | |
| SCHEMBL10312218 | 0.90 | NTRK1 (0.44) | GRK6AURKANTRK1CHEK1JAK2 | |
| SCHEMBL10312096 | 0.89 | MELK (0.34) | GRK6AURKA | |
| SCHEMBL10312097 | 0.86 | NTRK1 (0.53) | NTRK1JAK2JAK3 | |
| SCHEMBL10312205 | 0.85 | KCNH3 (0.40) | GRK6AURKANTRK1CHEK1CDK1 | |
| SCHEMBL10312198 | 0.79 | IGF1R (0.42) | — | |
| SCHEMBL10312203 | 0.79 | FLT3 (0.38) | AURKANTRK1CHEK1CDK1CDK4 | |
| SCHEMBL10312103 | 0.79 | HRH4 (0.47) | AURKANTRK1CHEK1CDK1CDK4 | |
| SCHEMBL10312197 | 0.79 | NTRK1 (0.42) | GRK6AURKANTRK1CHEK1JAK2 | |
| SCHEMBL10312078 | 0.79 | DHODH (0.41) | GRK6AURKANTRK1CHEK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | GRK6 101/4885AURKA 793/4885NTRK1 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.